Data presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, ...

Exploratory Phase 2 analysis shows Verrica’s novel oncolytic peptide, VP-315, reprograms the tumor microenvironment, increasing cytotoxic T-cell infiltration and reducing immunosuppressive ...

IAVI reports its single-dose Lassa fever vaccine is safe and effective, paving way for advanced trials across West Africa.

Volunteers were monitored for 12 months post-vaccination, with immune responses activating both humoral and cellular immunity ...

Doctor after doctor misdiagnosed or shrugged off Ruth Wilson’s rashes, swelling, fevers and severe pain for six years. She saved her life by begging for one more test in an emergency room about to ...

Pluribus opens with a world transformed by The Joining, a global hive mind event triggered by a cosmic signal. Only 13 people ...

Felzartamab, an investigational anti-CD38 monoclonal antibody, is a potentially differentiated therapeutic candidate with promise for a broad range of immune-mediated diseases ...

Our latest Focus Issue looks at what we’ve learnt over the past decade and what’s next for the field of trained immunity.